Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
QronsQRON EV-to-EBIT is 164.67 as of Jul. 30, 2026.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Qrons's Enterprise Value is $0.49 Mil.
Qrons's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil. Therefore, Qrons's EV-to-EBIT for today is 164.67.
The historical rank and industry rank for Qrons's EV-to-EBIT or its related term are showing as below:
QRON's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 12.165 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Qrons's Enterprise Value for the quarter that ended in Dec. 2024 was $3.52 Mil.
Qrons's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qrons EV-to-EBIT Related Terms
Qrons EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Qrons's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Qrons's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qrons EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qrons's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Qrons's EV-to-EBIT falls into.
Qrons's current Enterprise Value is $0.49 Mil.
Qrons's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qrons (QRON) has a EV-to-EBIT of 164.67 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Qrons and its competitors.
Is Qrons' EV-to-EBIT too high?
Qrons' current EV-to-EBIT is 164.67. The Biotechnology industry median EV-to-EBIT is 12.17. Qrons' value of 164.67 is 1253.6% above this industry median.
How does Qrons' EV-to-EBIT compare to GBLX and ENDV?
Qrons' EV-to-EBIT of 164.67 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 12.17. Qrons' value of 164.67 is 1253.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.17, based on 384 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qrons's current EV-to-EBIT of 164.67 is 1253.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Qrons and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qrons's current EV-to-EBIT is 164.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qrons stock overvalued right now?
Qrons (QRON) has a current EV-to-EBIT of 164.67. The current EV-to-EBIT is 164.67 and 1253.6% above the Biotechnology industry median of 12.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Qrons (QRON), the current EV-to-EBIT is 164.67 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qrons Inc. is a biotechnology company, dedicated to developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic-resistant bacteria, which is becoming the prominent and rapidly growing world-wide cause of illness and death. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM for treating concussions and other diffused axonal injuries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QRON has been successfully added to your 
